Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 8/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810011 | 0.90 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1PTPN11PTPN1PTPN6 | |
| SCHEMBL810047 | 0.85 | PLA2G4B (0.56) | PLA2G4B | |
| SCHEMBL13418164 | 0.84 | PTGDR2 (0.47) | CYSLTR2CYSLTR1PPARDALDH1A1KMT2A | |
| SCHEMBL809926 | 0.84 | ALDH1A1 (0.50) | CYSLTR2CYSLTR1PPARDALDH1A1KMT2A | |
| SCHEMBL13418134 | 0.78 | PPARD (0.40) | CYSLTR2CYSLTR1PTPN11PPARDALDH1A1 | |
| SCHEMBL25788077 | 0.77 | PTPN11 (0.67) | PTPN11PTPN1PTPN6PLA2G4BS1PR3 | |
| SCHEMBL9417624 | 0.77 | PTPN11 (0.67) | PTPN11PTPN1PTPN6PLA2G4BS1PR3 | |
| SCHEMBL810141 | 0.76 | ALDH1A1 (0.40) | PTPN11PPARDALDH1A1KMT2A | |
| SCHEMBL35211213 | 0.76 | PTPN11 (0.64) | PTPN11PTPN1PTPN6PLA2G4BS1PR3 | |
| SCHEMBL16190196 | 0.75 | PTPN11 (0.59) | PTPN11PTPN1PTPN6PLA2G4BS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902319-B2 | Unsymmetrical aromatic ether diacids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100113592-A1 | UNSYMMETRICAL AROMATIC ETHER DIACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2010-05-06 | — | — | US | disclosed |
| US-7671168-B2 | Unsymmetrical aromatic ether diacids and absorbable polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070141113-A1 | UNSYMMETRICAL AROMATIC ETHER DIACIDS AND ABSORBABLE POLYMERS THEREFROM | BEZWADA BIOMEDICAL, LLC (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113592-A1 | UNSYMMETRICAL AROMATIC ETHER DIACIDS AND ABSORBABLE POLYMERS THEREFROM | DDT, ACMSD, HPD | CYSLTR2 3949/4885CYSLTR1 3677/4885PTPN11 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.